Epithelial origin of eosinophilic esophagitis - 04/07/18
Abstract |
Eosinophilic esophagitis (EoE) is a chronic, allergen-driven inflammatory disease of the esophagus characterized predominantly by eosinophilic inflammation, leading to esophageal dysfunction. Converging data have placed the esophageal epithelium at the center of disease pathogenesis. In particular, the main EoE disease susceptibility loci at 2p23 and 5p22 encode for gene products that are produced by the esophageal epithelium: the intracellular protease calpain 14 and thymic stromal lymphopoietin, respectively. Furthermore, genetic and functional data establish a primary role for impaired epithelial barrier function in disease susceptibility and pathoetiology. Additionally, the EoE transcriptome, a set of genes dysregulated in the esophagi of patients with EoE, is enriched in genes that encode for proteins involved in esophageal epithelial cell differentiation. This transcriptome has a high proportion of esophagus-specific epithelial genes that are notable for the unexpected enrichment in genes encoding for proteases and protease inhibitors, as well as in IL-1 family genes, demonstrating a previously unappreciated role for innate immunity responses in the esophagus under homeostatic conditions. Among these pathways, basal production of the serine protease inhibitor, Kazal-type 7 (SPINK7) has been demonstrated to be part of the normal differentiation program of esophageal epithelium. Profound lost expression of SPINK7 occurs in patients with EoE and is sufficient for unleashing increased proteolytic activity (including urokinase plasminogen activator), impaired barrier function, and production of large quantities of proinflammatory and proallergic cytokines, including thymic stromal lymphopoietin. Collectively, we put forth a model in which the esophagus is normally equipped as an anti-inflammatory sensing organ and that defects in this pathway, mediated by epithelial protease/protease inhibitor imbalances, unleash inflammatory responses resulting in disorders, such as EoE.
Le texte complet de cet article est disponible en PDF.Key words : Eosinophilic esophagitis, eosinophilic oesophagitis, esophageal epithelium, epithelial differentiation, epithelial barrier, proteases, protease inhibitors, serine protease inhibitors, Kazal type
Abbreviations used : AD, ALI, BMP, CAPN14, CST, DSC, DSG1, DSP, EDC, EMSY (C11ORF30), EMT, EoE, FA, FLG, FST, GWAS, IBF, IBL, IVL, KLK, KRT, LRRC32, NKX2.1, PAR2, PBL, SERPIN, SNP, SOX2, SPINK, SPRR, STAT, SYNPO, TAC, TGM, TSLP, uPA, uPAR, WES
Plan
This work was supported in part by National Institutes of Health (NIH) grant R01 AI124355, NIH grant R37 A1045898, NIH grant U19 AI070235, the Campaign Urging Research for Eosinophilic Disease (CURED) Foundation, the Sunshine Charitable Foundation and its supporters, Denise A. Bunning and David G. Bunning, as well as CEGIR (U54 AI117804) as part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), National Center for Advancing Translational Sciences (NCATS), which is co-funded by National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), and NCATS. CEGIR is also supported by patient advocacy groups including the American Partnership for Eosinophilic Disorders (APFED), Campaign Urging Research for Eosinophilic Disease (CURED), and Eosinophilic Family Coalition (EFC). |
|
Disclosure of potential conflict of interest: M. E. Rothenberg is a consultant for PulmOne, Spoon Guru, ClostraBio, Celgene, Shire, AstraZeneca, GlaxoSmithKline, Allakos, Adare, Regeneron, and Novartis; has an equity interest in the first 4 listed companies and Immune Pharmaceuticals; and has received royalties from reslizumab (Teva Pharmaceuticals) and UpToDate. M. Rochman, N. P. Azouz, and M. E. Rothenberg are inventors of patents owned by Cincinnati Children's Hospital Medical Center. |
|
Terms in boldface and italics are detailed in the glossary on page 12. |
Vol 142 - N° 1
P. 10-23 - juillet 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?